Please login to the form below

Not currently logged in
Email:
Password:

Shires's Jeffrey Jonas to lead Sage

CNS appoints CEO alongside new CMO and CFO

Jeffrey Jones, Sage TherapeuticsSage Therapeutics has made several changes at the top level, including the appointment of Shire's Dr Jeffrey Jonas as CEO.

The other key appointments are AstraZeneca's Stephen Kanes as chief medical officer and Santhera's Kimi Iguchi as chief financial officer.

The changes come two years after the formation of the central nervous system (CNS) specialist and signal the expected growth of Sage as it moves its research programmes into late-stage development.

This will be headed by Dr Jonas (pictured), who was president of regenerative medicines at Shire and has a career in the life sciences that spans more than 20 years and includes CNS experience.

His roles prior to joining Shire include serving as executive VP of Isis Pharmaceuticals and chief medical officer of Forest Laboratories.

Dr Jonas also has entrepreneurial experience, founding Avax technologies and Sceptor Industries.

His new colleagues include Dr Kanes, who was most recently executive director/ therapeutic area clinical director for the inflammation, neuroscience and respiratory GMED division of AZ.

Dr Kanes also has experience as a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine

Iguchi joins from her role as chief operating officer, North America, for Santhera.

Her previous positions include VP, finance, for Cyberkinetics Neurotechnology Systems, as well as senior financial roles at Biogen and Millennium Pharmaceuticals.

16th August 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics